ID   Jurkat
AC   CVCL_0065
SY   JURKAT; JM; JM-Jurkat; Jurkat-FHCRC; Jurkat FHCRC; FHCRC-11; FHCRC subclone 11; FCCH1024
DR   BTO; BTO:0000661
DR   CLO; CLO_0007029
DR   CLO; CLO_0007043
DR   CLO; CLO_0050978
DR   CLO; CLO_0050993
DR   CLO; CLO_0051001
DR   EFO; EFO_0002796
DR   MCCL; MCC:0000503
DR   CLDB; cl2950
DR   CLDB; cl2959
DR   CLDB; cl2960
DR   CLDB; cl2961
DR   CLDB; cl5212
DR   Abcam; ab271143
DR   Abcam; ab275468
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-MTAB-3610
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   BioGRID_ORCS_Cell_line; 1255
DR   BioSample; SAMN03472181
DR   BioSample; SAMN03472286
DR   BioSample; SAMN03473341
DR   BioSample; SAMN10988565
DR   cancercelllines; CVCL_0065
DR   CCRID; 1101HUM-PUMC000347
DR   Cell_Model_Passport; SIDM01016
DR   ChEMBL-Cells; CHEMBL3307526
DR   ChEMBL-Targets; CHEMBL397
DR   CLS; 302147
DR   CLS; 305018
DR   Cosmic; 683539
DR   Cosmic; 721707
DR   Cosmic; 755289
DR   Cosmic; 801727
DR   Cosmic; 850196
DR   Cosmic; 913426
DR   Cosmic; 919152
DR   Cosmic; 922675
DR   Cosmic; 933540
DR   Cosmic; 991544
DR   Cosmic; 998737
DR   Cosmic; 999757
DR   Cosmic; 1012072
DR   Cosmic; 1037693
DR   Cosmic; 1115592
DR   Cosmic; 1118463
DR   Cosmic; 1118464
DR   Cosmic; 1127262
DR   Cosmic; 1130236
DR   Cosmic; 1132774
DR   Cosmic; 1175129
DR   Cosmic; 1191689
DR   Cosmic; 1224368
DR   Cosmic; 1226860
DR   Cosmic; 1330489
DR   Cosmic; 1375588
DR   Cosmic; 1483364
DR   Cosmic; 1524798
DR   Cosmic; 1639637
DR   Cosmic; 1641380
DR   Cosmic; 1664522
DR   Cosmic; 1760524
DR   Cosmic; 1811157
DR   Cosmic; 2039520
DR   Cosmic; 2165713
DR   Cosmic; 2301569
DR   Cosmic; 2361366
DR   Cosmic; 2602916
DR   Cosmic; 2750872
DR   Cosmic-CLP; 998184
DR   DepMap; ACH-000995
DR   DSMZ; ACC-282
DR   DSMZCellDive; ACC-282
DR   ECACC; 86010201
DR   EGA; EGAS00001000978
DR   EGA; EGAS00001002554
DR   GDSC; 998184
DR   GEO; GSM1991
DR   GEO; GSM236783
DR   GEO; GSM236819
DR   GEO; GSM482494
DR   GEO; GSM749672
DR   GEO; GSM887188
DR   GEO; GSM888261
DR   GEO; GSM1040307
DR   GEO; GSM1040377
DR   GEO; GSM1374580
DR   GEO; GSM1669965
DR   GEO; GSM5137718
DR   GEO; GSM5534218
DR   GEO; GSM5534219
DR   GEO; GSM5534220
DR   GEO; GSM5534221
DR   GEO; GSM5534222
DR   GEO; GSM5534223
DR   HIVReagentProgram; ARP-4668
DR   IARC_TP53; 186
DR   IBRC; C10155
DR   ICLC; HTL01002
DR   IHW; IHW00002
DR   IZSLER; BS CL 131
DR   KCB; KCB 94018YJ
DR   LiGeA; CCLE_029
DR   LINCS_LDP; LCL-2107
DR   Lonza; 142
DR   MeSH; D019169
DR   NCBI_Iran; C120
DR   PharmacoDB; JURKAT_712_2019
DR   PRIDE; PRD000008
DR   PRIDE; PRD000013
DR   PRIDE; PXD000443
DR   PRIDE; PRD000787
DR   PRIDE; PXD000426
DR   PRIDE; PXD001428
DR   PRIDE; PXD001872
DR   PRIDE; PXD002091
DR   PRIDE; PXD002395
DR   PRIDE; PXD006201
DR   PRIDE; PXD023662
DR   PRIDE; PXD030304
DR   Progenetix; CVCL_0065
DR   PubChem_Cell_line; CVCL_0065
DR   RCB; RCB0537
DR   RCB; RCB0806
DR   RCB; RCB3052
DR   TKG; TKG 0209
DR   TOKU-E; 3710
DR   Wikidata; Q1632589
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=68013;
RX   PubMed=204546;
RX   PubMed=1086134;
RX   PubMed=1103999;
RX   PubMed=1915666;
RX   PubMed=2144611;
RX   PubMed=2985879;
RX   PubMed=3159941;
RX   PubMed=3165345;
RX   PubMed=3874327;
RX   PubMed=8127147;
RX   PubMed=8547074;
RX   PubMed=8558913;
RX   PubMed=8641406;
RX   PubMed=8957066;
RX   PubMed=9510473;
RX   PubMed=9583678;
RX   PubMed=9685479;
RX   PubMed=9738977;
RX   PubMed=9787181;
RX   PubMed=9933131;
RX   PubMed=10071127;
RX   PubMed=10739008;
RX   PubMed=11021758;
RX   PubMed=11226526;
RX   PubMed=15028022;
RX   PubMed=15472075;
RX   PubMed=16408098;
RX   PubMed=17117183;
RX   PubMed=17170727;
RX   PubMed=19220422;
RX   PubMed=19473701;
RX   PubMed=19608861;
RX   PubMed=22278370;
RX   PubMed=22460905;
RX   PubMed=22675565;
RX   PubMed=22944676;
RX   PubMed=23325432;
RX   PubMed=24618588;
RX   PubMed=26074081;
RX   PubMed=27397505;
RX   PubMed=28357668;
RX   PubMed=29967540;
RX   PubMed=30285677;
RX   PubMed=30629668;
RX   PubMed=30844424;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31160637;
RX   PubMed=31978347;
RX   PubMed=35354797;
RX   PubMed=35839778;
WW   https://en.wikipedia.org/wiki/Jurkat_cells
WW   http://www.cells-talk.com/index.php/page/copelibrary?key=Jurkat
WW   http://141.61.102.20/mxdb/project/show/9191407937500
WW   http://genome.ucsc.edu/ENCODE/protocols/cell/human/Jurkat_protocol.pdf
WW   https://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/j/cell-lines-detail-7.html
CC   Group: Space-flown cell line (cellonaut).
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Part of: ENCODE project common cell types; tier 3.
CC   Part of: International Histocompatibility Workshop cell lines.
CC   Part of: LL-100 blood cancer cell line panel.
CC   Population: Caucasian.
CC   Doubling time: 26 hours (PubMed=17117183); ~25-35 hours (DSMZ=ACC-282).
CC   HLA typing: A*03:01:01,03:01:01; B*07:02:01,35:03:01; C*04:01:01,07:02:01; DQB1*06:03:01,06:03:01 (DSMZCellDive=ACC-282).
CC   Microsatellite instability: Instable (MSI-high) (PubMed=10739008; PubMed=11226526; PubMed=31068700; Sanger).
CC   Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (PubMed=9583678).
CC   Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (PubMed=9583678).
CC   Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (PubMed=22675565; Cosmic-CLP).
CC   Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (PubMed=19473701).
CC   Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (PubMed=19473701).
CC   Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (PubMed=9583678).
CC   Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (PubMed=9510473).
CC   Sequence variation: Mutation; HGNC; 7881; NOTCH1; Simple; p.Arg1627His (c.4880G>A); ClinVar=VCV000409067; Zygosity=Heterozygous (PubMed=15472075).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (PubMed=2144611; PubMed=10071127; PubMed=19220422; PubMed=22675565; Cosmic-CLP).
CC   Omics: Acetylation analysis by proteomics.
CC   Omics: Deep exome analysis.
CC   Omics: DNA methylation analysis.
CC   Omics: Deep phosphoproteome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: HLA class I peptidome analysis by proteomics.
CC   Omics: N-glycan profiling.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Omics: Ubiquitination analysis by proteomics.
CC   Omics: Virome analysis using proteomics.
CC   Genome ancestry: African=0.4%; Native American=0%; East Asian, North=0.13%; East Asian, South=1.21%; South Asian=1.08%; European, North=70.73%; European, South=26.45% (PubMed=30894373).
CC   Anecdotal: Have been flown in space on Cosmos-2044 to study the inhibition of phorbol ester-induced cell activation in microgravity (PubMed=1915666).
CC   Misspelling: Jurcat; Note=Occasionally.
CC   Misspelling: JURKET; PubMed=313568.
CC   Discontinued: CLS; 305018; true.
CC   Discontinued: ICLC; HTL01002; true.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
ST   Source(s): CCRID; COG; Cosmic-CLP; DSMZ; ECACC; PubMed=28357668; RCB; TKG
ST   Amelogenin: X,Y
ST   CSF1PO: 9,10,11 (RCB_RCB0537)
ST   CSF1PO: 10,11 (Cosmic-CLP; DSMZ)
ST   CSF1PO: 10,12 (ECACC)
ST   CSF1PO: 11 (RCB_RCB0806)
ST   CSF1PO: 11,12 (CCRID; COG; PubMed=28357668; TKG)
ST   D13S317: 8,10,11 (TKG)
ST   D13S317: 8,11 (COG; Cosmic-CLP; DSMZ; ECACC; RCB_RCB0537)
ST   D13S317: 8,11,12 (RCB_RCB0806)
ST   D13S317: 8,12 (CCRID; PubMed=28357668)
ST   D16S539: 10,11 (ECACC; RCB_RCB0537)
ST   D16S539: 11 (CCRID; COG; Cosmic-CLP; DSMZ; PubMed=28357668; RCB_RCB0806; TKG)
ST   D18S51: 13,14,20,21 (DSMZ)
ST   D18S51: 13,21 (CCRID; PubMed=28357668)
ST   D19S433: 13,15.2 (COG; PubMed=28357668)
ST   D19S433: 13,16 (DSMZ)
ST   D19S433: 14,15.2 (CCRID)
ST   D21S11: 31.2,32.2 (COG)
ST   D21S11: 31.2,33.2 (CCRID; PubMed=28357668)
ST   D21S11: 31.2,32.2,33.2 (DSMZ)
ST   D2S1338: 19,23 (CCRID; COG)
ST   D2S1338: 19,23,24 (DSMZ)
ST   D3S1358: 15 (CCRID)
ST   D3S1358: 15,16,17 (COG; DSMZ)
ST   D3S1358: 15,17 (PubMed=28357668)
ST   D5S818: 9
ST   D7S820: 8,10 (CCRID; COG; ECACC; RCB_RCB0537; TKG)
ST   D7S820: 8,10,11 (Cosmic-CLP; DSMZ; RCB_RCB0806)
ST   D7S820: 8,12 (PubMed=28357668)
ST   D8S1179: 12,14,15 (COG)
ST   D8S1179: 13 (DSMZ)
ST   D8S1179: 13,14 (CCRID; PubMed=28357668)
ST   FGA: 20,21 (CCRID; PubMed=28357668)
ST   FGA: 20,21,22 (DSMZ)
ST   FGA: 20,22 (COG)
ST   Penta D: 11,13
ST   Penta E: 9,10,12 (DSMZ)
ST   Penta E: 10,12 (PubMed=28357668)
ST   TH01: 6,9.3
ST   TPOX: 8,9,10 (RCB_RCB0537)
ST   TPOX: 8,10 (CCRID; COG; Cosmic-CLP; DSMZ; ECACC; PubMed=28357668; RCB_RCB0806; TKG)
ST   vWA: 16,17,18 (RCB_RCB0537; RCB_RCB0806)
ST   vWA: 16,17,19,20 (ECACC)
ST   vWA: 17,18,19 (COG)
ST   vWA: 17,18,19,20 (DSMZ)
ST   vWA: 18 (CCRID; PubMed=28357668)
ST   vWA: 18,19,20 (Cosmic-CLP)
ST   vWA: 18,20 (TKG)
DI   NCIt; C7953; Childhood T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   14Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 30-01-24; Version: 44
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001).
//
RX   PubMed=68013; DOI=10.1002/ijc.2910190505;
RA   Schneider U., Schwenk H.-U., Bornkamm G.-W.;
RT   "Characterization of EBV-genome negative 'null' and 'T' cell lines
RT   derived from children with acute lymphoblastic leukemia and leukemic
RT   transformed non-Hodgkin lymphoma.";
RL   Int. J. Cancer 19:621-626(1977).
//
RX   PubMed=204546; DOI=10.1007/978-3-642-66639-1_32;
RA   Schneider U., Schwenk H.-U.;
RT   "Characterization of 'T' and 'non-T' cell lines established from
RT   children with acute lymphoblastic leukemia and non-Hodgkin lymphoma
RT   after leukemic transformation.";
RL   Haematol. Blood Transfus. 20:265-269(1977).
//
RX   PubMed=1086134;
RA   Kaplan J., Peterson W.D. Jr.;
RT   "Detection of T-cell lymphoma-associated antigens on cord blood
RT   lymphocytes and phytohemagglutinin-stimulated blasts.";
RL   Cancer Res. 36:3471-3475(1976).
//
RX   PubMed=1103999; DOI=10.1007/BF01634146;
RA   Schwenk H.-U., Schneider U.;
RT   "Cell cycle dependency of a T-cell marker on lymphoblasts.";
RL   Blut 31:299-306(1975).
//
RX   PubMed=1915666; DOI=10.1016/0014-4827(91)90482-A;
RA   Limouse M., Manie S., Konstantinova I., Ferrua B., Schaffar L.;
RT   "Inhibition of phorbol ester-induced cell activation in
RT   microgravity.";
RL   Exp. Cell Res. 197:82-86(1991).
//
RX   PubMed=2144611; DOI=10.1128/mcb.10.10.5502-5509.1990;
RA   Cheng J., Haas M.;
RT   "Frequent mutations in the p53 tumor suppressor gene in human leukemia
RT   T-cell lines.";
RL   Mol. Cell. Biol. 10:5502-5509(1990).
//
RX   PubMed=2985879; DOI=10.1016/0145-2126(85)90084-0;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- 1.
RT   carboxylic esterase.";
RL   Leuk. Res. 9:209-229(1985).
//
RX   PubMed=3159941; DOI=10.1016/0145-2126(85)90134-1;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cell lines -- III.
RT   Beta-hexosaminidase (E.C. 3.2.1.30).";
RL   Leuk. Res. 9:549-559(1985).
//
RX   PubMed=3165345;
RA   LaGree K.A., Lee A.T., Stetten G., Strauss P.R.;
RT   "The human Jurkat (FHCRC-11) cell line is heterogeneous in ploidy and
RT   cell size and releases detergent-soluble DNA.";
RL   Exp. Hematol. 16:686-690(1988).
//
RX   PubMed=3874327; DOI=10.1016/0145-2126(85)90133-x;
RA   Drexler H.G., Gaedicke G., Minowada J.;
RT   "Isoenzyme studies in human leukemia-lymphoma cells lines -- II. Acid
RT   phosphatase.";
RL   Leuk. Res. 9:537-548(1985).
//
RX   PubMed=8127147;
RA   Heyman M., Grander D., Brondum-Nielsen K., Cederblad B., Liu Y.,
RA   Xu B., Einhorn S.;
RT   "Interferon system defects in malignant T-cells.";
RL   Leukemia 8:425-434(1994).
//
RX   PubMed=8547074; DOI=10.1111/j.1365-2141.1995.tb05302.x;
RA   Siebert R., Willers C.P., Schramm A., Fossa A., Dresen I.M.G.,
RA   Uppenkamp M., Nowrousian M.R., Seeber S., Opalka B.;
RT   "Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and
RT   lymphoblastic leukaemia cell lines.";
RL   Br. J. Haematol. 91:350-354(1995).
//
RX   PubMed=8558913;
RA   Morita S., Tsuchiya S., Fujie H., Itano M., Ohashi Y., Minegishi M.,
RA   Imaizumi M., Endo M., Takano N., Konno T.;
RT   "Cell surface c-kit receptors in human leukemia cell lines and
RT   pediatric leukemia: selective preservation of c-kit expression on
RT   megakaryoblastic cell lines during adaptation to in vitro culture.";
RL   Leukemia 10:102-105(1996).
//
RX   PubMed=8641406; DOI=10.1111/j.1600-0609.1996.tb00721.x;
RA   Borgonovo-Brandter L., Heyman M., Rasool O., Liu Y., Grander D.,
RA   Einhorn S.;
RT   "p16INK4/p15INK4B gene inactivation is a frequent event in malignant
RT   T-cell lines.";
RL   Eur. J. Haematol. 56:313-318(1996).
//
RX   PubMed=8957066; DOI=10.1111/j.1349-7006.1996.tb03112.x;
RA   Kawasaki N., Matsuo Y., Yoshino T., Yanai H., Oka T., Teramoto N.,
RA   Liu C., Kondo E., Minowada J., Akagi T.;
RT   "Metastatic potential of lymphoma/leukemia cell lines in SCID mice is
RT   closely related to expression of CD44.";
RL   Jpn. J. Cancer Res. 87:1070-1077(1996).
//
RX   PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x;
RA   Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y.,
RA   Hirai H.;
RT   "Frameshift mutations of the hMSH6 gene in human leukemia cell
RT   lines.";
RL   Jpn. J. Cancer Res. 89:33-39(1998).
//
RX   PubMed=9583678; DOI=10.1038/sj.onc.1201704;
RA   Brimmell M., Mendiola R., Mangion J., Packham G.;
RT   "BAX frameshift mutations in cell lines derived from human
RT   haemopoietic malignancies are associated with resistance to apoptosis
RT   and microsatellite instability.";
RL   Oncogene 16:1803-1812(1998).
//
RX   PubMed=9685479; DOI=10.1093/nar/26.16.3651;
RA   Hultdin M., Gronlund E., Norrback K.-F., Eriksson-Lindstrom E., Just T.,
RA   Roos G.;
RT   "Telomere analysis by fluorescence in situ hybridization and flow
RT   cytometry.";
RL   Nucleic Acids Res. 26:3651-3656(1998).
//
RX   PubMed=9738977; DOI=10.1111/j.1349-7006.1998.tb03275.x;
RA   Takizawa J., Suzuki R., Kuroda H., Utsunomiya A., Kagami Y., Joh T.,
RA   Aizawa Y., Ueda R., Seto M.;
RT   "Expression of the TCL1 gene at 14q32 in B-cell malignancies but not
RT   in adult T-cell leukemia.";
RL   Jpn. J. Cancer Res. 89:712-718(1998).
//
RX   PubMed=9787181; DOI=10.1182/blood.V92.9.3410;
RA   Sakai A., Thieblemont C., Wellmann A., Jaffe E.S., Raffeld M.;
RT   "PTEN gene alterations in lymphoid neoplasms.";
RL   Blood 92:3410-3415(1998).
//
RX   PubMed=9933131; DOI=10.1016/S0145-2126(98)00133-7;
RA   Burger R., Hansen-Hagge T.E., Drexler H.G., Gramatzki M.;
RT   "Heterogeneity of T-acute lymphoblastic leukemia (T-ALL) cell lines:
RT   suggestion for classification by immunophenotype and T-cell receptor
RT   studies.";
RL   Leuk. Res. 23:19-27(1999).
//
RX   PubMed=10071127; DOI=10.1016/S0145-2126(98)00146-5;
RA   Kawamura M., Ohnishi H., Guo S.X., Sheng X.-M., Minegishi M.,
RA   Hanada R., Horibe K., Hongo T., Kaneko Y., Bessho F., Yanagisawa M.,
RA   Sekiya T., Hayashi Y.;
RT   "Alterations of the p53, p21, p16, p15 and RAS genes in childhood
RT   T-cell acute lymphoblastic leukemia.";
RL   Leuk. Res. 23:115-126(1999).
//
RX   PubMed=10739008; DOI=10.1016/S0145-2126(99)00182-4;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Frequent microsatellite instability and BAX mutations in T cell acute
RT   lymphoblastic leukemia cell lines.";
RL   Leuk. Res. 24:255-262(2000).
//
RX   PubMed=11021758; DOI=10.1038/sj.leu.2401891;
RA   Majka M., Rozmyslowicz T., Honczarenko M., Ratajczak J., Wasik M.A.,
RA   Gaulton G.N., Ratajczak M.Z.;
RT   "Biological significance of the expression of HIV-related chemokine
RT   coreceptors (CCR5 and CXCR4) and their ligands by human hematopoietic
RT   cell lines.";
RL   Leukemia 14:1821-1832(2000).
//
RX   PubMed=11226526; DOI=10.1016/S0145-2126(00)00121-1;
RA   Inoue K., Kohno T., Takakura S., Hayashi Y., Mizoguchi H., Yokota J.;
RT   "Corrigendum to: Frequent microsatellite instability and BAX mutations
RT   in T cell acute lymphoblastic leukemia cell lines Leukemia Research 24
RT   (2000),255-262.";
RL   Leuk. Res. 25:275-278(2001).
//
RX   PubMed=15028022; DOI=10.1111/j.1440-1827.2004.01612.x;
RA   Kamimura K., Hojo H., Abe M.;
RT   "Characterization of expression of protein kinase C isozymes in human
RT   B-cell lymphoma: relationship between its expression and prognosis.";
RL   Pathol. Int. 54:224-230(2004).
//
RX   PubMed=15472075; DOI=10.1126/science.1102160;
RA   Weng A.P., Ferrando A.A., Lee W., Morris J.P. IV, Silverman L.B.,
RA   Sanchez-Irizarry C., Blacklow S.C., Look A.T., Aster J.C.;
RT   "Activating mutations of NOTCH1 in human T cell acute lymphoblastic
RT   leukemia.";
RL   Science 306:269-271(2004).
//
RX   PubMed=16408098; DOI=10.1038/sj.leu.2404081;
RA   Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.;
RT   "JAK2 V617F tyrosine kinase mutation in cell lines derived from
RT   myeloproliferative disorders.";
RL   Leukemia 20:471-476(2006).
//
RX   PubMed=17117183; DOI=10.1038/sj.bjc.6603447;
RA   Beesley A.H., Palmer M.-L., Ford J., Weller R.E., Cummings A.J.,
RA   Freitas J.R., Firth M.J., Perera K.U., de Klerk N.H., Kees U.R.;
RT   "Authenticity and drug resistance in a panel of acute lymphoblastic
RT   leukaemia cell lines.";
RL   Br. J. Cancer 95:1537-1544(2006).
//
RX   PubMed=17170727; DOI=10.1038/sj.leu.2404486;
RA   Sandberg Y., Verhaaf B., van Gastel-Mol E.J., Wolvers-Tettero I.L.M.,
RA   de Vos J., MacLeod R.A.F., Noordzij J.G., Dik W.A., van Dongen J.J.M.,
RA   Langerak A.W.;
RT   "Human T-cell lines with well-defined T-cell receptor gene
RT   rearrangements as controls for the BIOMED-2 multiplex polymerase chain
RT   reaction tubes.";
RL   Leukemia 21:230-237(2007).
//
RX   PubMed=19220422; DOI=10.1111/j.1600-0609.2009.01211.x;
RA   Kamihira S., Terada C., Sasaki D., Yanagihara K., Tsukasaki K.,
RA   Hasegawa H., Yamada Y.;
RT   "Aberrant p53 protein expression and function in a panel of
RT   hematopoietic cell lines with different p53 mutations.";
RL   Eur. J. Haematol. 82:301-307(2009).
//
RX   PubMed=19473701; DOI=10.1016/j.leukres.2009.04.032;
RA   Lo T.C.T., Barnhill L.M., Kim Y., Nakae E.A., Yu A.L.-T.,
RA   Diccianni M.B.;
RT   "Inactivation of SHIP1 in T-cell acute lymphoblastic leukemia due to
RT   mutation and extensive alternative splicing.";
RL   Leuk. Res. 33:1562-1566(2009).
//
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M.,
RA   Walther T.C., Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
//
RX   PubMed=22278370; DOI=10.1074/mcp.M111.014050;
RA   Geiger T., Wehner A., Schaab C., Cox J., Mann M.;
RT   "Comparative proteomic analysis of eleven common cell lines reveals
RT   ubiquitous but varying expression of most proteins.";
RL   Mol. Cell. Proteomics 11:M111.014050-M111.014050(2012).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22675565; DOI=10.1371/journal.pone.0038463;
RA   Atak Z.K., De Keersmaecker K., Gianfelici V., Geerdens E.,
RA   Vandepoel R., Pauwels D., Porcu M., Lahortiga I., Brys V., Dirks W.G.,
RA   Quentmeier H., Cloos J., Cuppens H., Uyttebroeck A., Vandenberghe P.,
RA   Cools J., Aerts S.;
RT   "High accuracy mutation detection in leukemia on a selected panel of
RT   cancer genes.";
RL   PLoS ONE 7:E38463-E38463(2012).
//
RX   PubMed=22944676; DOI=10.1515/hsz-2012-0195;
RA   Reinke S.O., Bayer M., Berger M., Hinderlich S., Blanchard V.;
RT   "The analysis of N-glycans of cell membrane proteins from human
RT   hematopoietic cell lines reveals distinctions in their pattern.";
RL   Biol. Chem. 393:731-747(2012).
//
RX   PubMed=23325432; DOI=10.1101/gr.147942.112;
RA   Varley K.E., Gertz J., Bowling K.M., Parker S.L., Reddy T.E.,
RA   Pauli-Behn F., Cross M.K., Williams B.A., Stamatoyannopoulos J.A.,
RA   Crawford G.E., Absher D.M., Wold B.J., Myers R.M.;
RT   "Dynamic DNA methylation across diverse human cell lines and
RT   tissues.";
RL   Genome Res. 23:555-567(2013).
//
RX   PubMed=24618588; DOI=10.1371/journal.pone.0091433;
RA   Chernobrovkin A.L., Zubarev R.A.;
RT   "Detection of viral proteins in human cells lines by xeno-proteomics:
RT   elimination of the last valid excuse for not testing every cellular
RT   proteome dataset for viral proteins.";
RL   PLoS ONE 9:E91433-E91433(2014).
//
RX   PubMed=26074081; DOI=10.1016/j.celrep.2015.05.029;
RA   Giansanti P., Aye T.T., van den Toorn H., Peng M., van Breukelen B.,
RA   Heck A.J.R.;
RT   "An augmented multiple-protease-based human phosphopeptide atlas.";
RL   Cell Rep. 11:1834-1843(2015).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=28357668; DOI=10.1007/978-1-4939-6872-5_11;
RA   Raimondi V., Minuzzo S.A., Ciminale V., D'Agostino D.M.;
RT   "STR profiling of HTLV-1-infected cell lines.";
RL   Methods Mol. Biol. 1582:143-154(2017).
//
RX   PubMed=29967540; DOI=10.1038/s41594-018-0084-y;
RA   Akimov V., Barrio-Hernandez I., Hansen S.V.F., Hallenborg P.,
RA   Pedersen A.-K., Bekker-Jensen D.B., Puglia M., Christensen S.D.K.,
RA   Vanselow J.T., Nielsen M.M., Kratchmarova I., Kelstrup C.D.,
RA   Olsen J.V., Blagoev B.;
RT   "UbiSite approach for comprehensive mapping of lysine and N-terminal
RT   ubiquitination sites.";
RL   Nat. Struct. Mol. Biol. 25:631-640(2018).
//
RX   PubMed=30285677; DOI=10.1186/s12885-018-4840-5;
RA   Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X.,
RA   Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H.,
RA   Koeffler H.P.;
RT   "Profiling the B/T cell receptor repertoire of lymphocyte derived cell
RT   lines.";
RL   BMC Cancer 18:940.1-940.13(2018).
//
RX   PubMed=30629668; DOI=10.1371/journal.pone.0210404;
RA   Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.;
RT   "Screening human cell lines for viral infections applying RNA-Seq data
RT   analysis.";
RL   PLoS ONE 14:E0210404-E0210404(2019).
//
RX   PubMed=30844424; DOI=10.1016/j.humimm.2019.03.001;
RA   Creary L.E., Guerra S.G., Chong W., Brown C.J., Turner T.R.,
RA   Robinson J., Bultitude W.P., Mayor N.P., Marsh S.G.E., Saito K.,
RA   Lam K., Duke J.L., Mosbruger T.L., Ferriola D., Monos D.S., Willis A.,
RA   Askar M., Fischer G.F., Saw C.L., Ragoussis J., Petrek M.,
RA   Serra-Pages C., Juan Otero M., Stavropoulos-Giokas C., Dinou A., Ameen R.,
RA   Al Shemmari S., Spierings E., Gendzekhadze K., Morris G.P., Zhang Q.-H.,
RA   Kashi Z., Hsu S., Gangavarapu S., Mallempati K.C., Yamamoto F.,
RA   Osoegawa K., Vayntrub T., Chang C.-J., Hansen J.A.,
RA   Fernandez-Vina M.A.;
RT   "Next-generation HLA typing of 382 International Histocompatibility
RT   Working Group reference B-lymphoblastoid cell lines: report from the
RT   17th International HLA and Immunogenetics Workshop.";
RL   Hum. Immunol. 80:449-460(2019).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218-8218(2019).
//
RX   PubMed=31978347; DOI=10.1016/j.cell.2019.12.023;
RA   Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. III,
RA   Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K.,
RA   Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K.,
RA   Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A.,
RA   Sellers W.R., Gygi S.P.;
RT   "Quantitative proteomics of the Cancer Cell Line Encyclopedia.";
RL   Cell 180:387-402.e16(2020).
//
RX   PubMed=35354797; DOI=10.1038/s41467-022-29224-5;
RA   Leo I.R., Aswad L., Stahl M., Kunold E., Post F., Erkers T.,
RA   Struyf N., Mermelekas G., Joshi R.N., Gracia-Villacampa E.,
RA   Ostling P., Kallioniemi O.-P., Pokrovskaja Tamm K., Siavelis I.,
RA   Lehtio J., Vesterlund M., Jafari R.;
RT   "Integrative multi-omics and drug response profiling of childhood
RT   acute lymphoblastic leukemia cell lines.";
RL   Nat. Commun. 13:1691.1-1691.19(2022).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//